Immix Biopharma To Present An NXC-201 Abstract At American Society Of Hematology Annual Meeting, December 12-15
Benzinga Newsdesk 6 days ago
News
ASH Oral Presentation Details:Event 68th ASH Annual Meeting and Exposition, New Orleans, LATitle "45-patient safety and efficacy data for NXC-201 from Nexicart-2, the first U.S. trial of CAR-T in
ASH Oral Presentation Details:
Event 68th ASH Annual Meeting and Exposition, New Orleans, LA
Title "45-patient safety and efficacy data for NXC-201 from Nexicart-2, the first U.S. trial of CAR-T in relapsed/refractory AL amyloidosis"
Presentation
Date/Time (Central Time)
Publication #826
Session Date: Monday, December 14, 2026
Session Name: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Advancing Treatment Strategies in AL Amyloidosis
Session Time: 10:30 AM -12:00 PM
Presentation Time: 11:15 AM